Viplus Pharmaceuticals Private Limited
About Viplus Pharmaceuticals Private Limited
Data last updated: 06 February 2026
Viplus Pharmaceuticals Private Limited is a private limited company based in Kukatpally, Telangana, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 03 November 2020, the company has been in operation for over 6 years.
Registered with ROC Hyderabad under CIN U24299TG2020PTC145526.
Capital: an authorised share capital of ₹4.01 Cr and a paid-up capital of ₹2.01 Cr. It is led by directors including Prakash Reddy Vinta and Satwick Reddy Vinta.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Flat No. 104 Block No.2 Hydernagar Village, Kukatpally, Telangana, India – 500085.
As per the financials filed for FY 2024, the company reported a revenue of ₹109.48 Cr, a growth of 83% compared to the previous year.
As per MCA filings, the company has open charges of ₹30.86 Cr and satisfied charges of ₹15 Cr on record.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website**************
-
Social Media**************
-
Registered AddressFlat No. 104 Block No.2 Hydernagar Village, Kukatpally, Telangana, India – 500085
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Business Activity of Viplus Pharmaceuticals Private Limited
Viplus Pharmaceuticals Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Viplus Pharmaceuticals Private Limited
Viplus Pharmaceuticals Private Limited is audited by Shah Baxi & Associates for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Shah Baxi & Associates | blur-value | blur-value | blur-value |
Board of Directors of Viplus Pharmaceuticals Private Limited
Viplus Pharmaceuticals Private Limited is currently managed by 3 directors, with 1 former director having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Prakash Reddy Vinta | Director | 03 Nov 2020 | 5 Years 8 Months | Current |
|
Satwick Reddy Vinta
Also directs:
Nk Chemicals Pvt Ltd, Aditri Pharma Sciences Private Limited
|
Director | 03 Nov 2022 | 3 Years 8 Months | Current |
|
Sashank Reddy Vinta
Also directs:
Vinta Laboratories Private Limited, Vinta Labs Private Limited, Care-Ind Chem Private Limited and 2 more
|
Director | 03 Nov 2020 | 5 Years 8 Months | Current |
Financials of Viplus Pharmaceuticals Private Limited FY 2024 filings available
Viplus Pharmaceuticals Private Limited reported revenue of ₹109.48 Cr (up 83% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Viplus Pharmaceuticals Private Limited
As of FY 2024, Viplus Pharmaceuticals Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Viplus Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Jan 2026 | Others | ₹25.5 Lakh | Open |
| 04 Aug 2023 | Axis Bank Limited | ₹29.95 Cr | Open |
| 29 Jun 2023 | Others | ₹65 Lakh | Open |
| 31 Jan 2022 | Others | ₹15 Cr | Satisfied |
Total charge records: 4 View all charges
Employees and EPFO Compliance at Viplus Pharmaceuticals Private Limited
Viplus Pharmaceuticals Private Limited has a workforce of 0 employees as of Sep 25, 2025.
Employee Count & EPFO Data of Viplus Pharmaceuticals Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Viplus Pharmaceuticals Private Limited
GSTIN & GST Filing Data of Viplus Pharmaceuticals Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Viplus Pharmaceuticals Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Viplus Pharmaceuticals Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Viplus Pharmaceuticals Private Limited
MSME Payment Delays by Viplus Pharmaceuticals Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Viplus Pharmaceuticals Private Limited
Subsidiaries & Group Companies of Viplus Pharmaceuticals Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Viplus Pharmaceuticals Private Limited with ownership details.
MCA Filings & Documents of Viplus Pharmaceuticals Private Limited
MCA Filings & Documents of Viplus Pharmaceuticals Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Viplus Pharmaceuticals Private Limited
Frequently Asked Questions about Viplus Pharmaceuticals Private Limited
Viplus Pharmaceuticals Private Limited is an active private limited company in the pharma sector based in Kukatpally, Telangana, India. It was incorporated on 03 November 2020 (6+ years old) and is registered under CIN U24299TG2020PTC145526.
Viplus Pharmaceuticals Private Limited reported revenue of ₹109.48 Cr for FY 2024 (up 83.00% YoY).
The current directors of Viplus Pharmaceuticals Private Limited are:
The primary industry of Viplus Pharmaceuticals Private Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Viplus Pharmaceuticals Private Limited can be reached at the registered office: Flat No. 104 Block No.2 Hydernagar Village, Kukatpally, Telangana, India – 500085.
The authorised capital is ₹4.01 Cr, and the paid-up capital is ₹2.01 Cr.